News
Prophylactic itacitinib reduces the risk for cytokine release syndrome in immune effector cell therapy, new research suggests.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback